Glycemic Improvement with Low-Dose Dulaglutide Is Associated with Leptin and Obestatin Modulation in Type 2 Diabetes Mellitus.

Jung I, Choi H, Choi IY, Cho HJ, Park SY, Lee DY, Seo JA, Kim NH, Yu JH

Diabetes & metabolism journal24 Nov 2025Cited by 1 (Europe PMC)

PMID41277001PMCIDPMC13175701DOI10.4093/dmj.2025.0681PepBankPUB-41277001

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In patients with T2DM who completed treatment, dulaglutide was linked to significantly lower HbA1c than baseline.
In plain wordsIn patients with diabetes who completed treatment, dulaglutide use was linked to lower HbA1c than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Among the 67 patients who completed the study, dulaglutide significantly reduced HbA1c, food cravings, leptin, and adiponectin levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
Report a problemFND-4127700101
02HumanObservational studyEfficacy outcome
In patients with T2DM who completed treatment, dulaglutide was linked to significantly fewer food cravings than baseline.
In plain wordsIn patients with diabetes who completed treatment, dulaglutide use was linked to fewer food cravings than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFood cravings
Study
n = 67
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.75 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Among the 67 patients who completed the study, dulaglutide significantly reduced HbA1c, food cravings, leptin, and adiponectin levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
Report a problemFND-4127700102
03HumanObservational studyEfficacy outcome
In patients with T2DM who completed treatment, dulaglutide was linked to significantly lower leptin levels than baseline.
In plain wordsIn patients with diabetes who completed treatment, dulaglutide use was linked to lower leptin levels than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLeptin levels
Study
n = 67
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.75 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Among the 67 patients who completed the study, dulaglutide significantly reduced HbA1c, food cravings, leptin, and adiponectin levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
Report a problemFND-4127700103
04HumanObservational studyEfficacy outcome
In patients with T2DM who completed treatment, dulaglutide was linked to significantly lower adiponectin levels than baseline.
In plain wordsIn patients with diabetes who completed treatment, dulaglutide use was linked to lower adiponectin levels than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseAdiponectin levels
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Among the 67 patients who completed the study, dulaglutide significantly reduced HbA1c, food cravings, leptin, and adiponectin levels.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
Report a problemFND-4127700104
05HumanObservational studyEfficacy outcome
In patients with T2DM, obestatin levels increased modestly during dulaglutide treatment.
In plain wordsIn patients with diabetes, obestatin levels rose modestly during dulaglutide treatment compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseObestatin levels
Study
n = 67
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.75 mg once weekly · 24 weeksAs given in this study (human).
Source sentences
Summary
Obestatin levels increased modestly.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
Report a problemFND-4127700105

Studies that did not test the peptide alone7

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
During dulaglutide treatment in T2DM, decreased leptin was independently associated with HbA1c reduction.
In plain wordsIn patients with diabetes receiving dulaglutide, lower leptin was linked to reduced HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableLeptin change association with HbA1c
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In the adjusted models, a decrease in leptin and an increase in obestatin were independently associated with HbA1c reduction, while decreased adiponectin was associated with poorer glycemic outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700108
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
During dulaglutide treatment in T2DM, increased obestatin was independently associated with HbA1c reduction.
In plain wordsIn patients with diabetes receiving dulaglutide, increased obestatin was linked to reduced HbA1c.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableObestatin change association with HbA1c
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In the adjusted models, a decrease in leptin and an increase in obestatin were independently associated with HbA1c reduction, while decreased adiponectin was associated with poorer glycemic outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700109
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
During dulaglutide treatment in T2DM, decreased adiponectin was associated with poorer glycemic outcomes.
In plain wordsIn patients with diabetes receiving dulaglutide, reduced adiponectin was linked to poorer blood sugar outcomes.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAdiponectin change association with glycemia
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In the adjusted models, a decrease in leptin and an increase in obestatin were independently associated with HbA1c reduction, while decreased adiponectin was associated with poorer glycemic outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700110
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
During dulaglutide treatment in T2DM, BMI changes were not associated with glycemic improvement.
In plain wordsIn patients with diabetes receiving dulaglutide, BMI changes were not linked to better blood sugar control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeBMI change association with glycemic improvement
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Changes in body mass index or abdominal fat were not associated with glycemic improvement.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700111
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
During dulaglutide treatment in T2DM, abdominal fat changes were not associated with glycemic improvement.
In plain wordsIn patients with diabetes receiving dulaglutide, abdominal fat changes were not linked to better blood sugar control.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAbdominal fat change association with glycemic improvement
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Changes in body mass index or abdominal fat were not associated with glycemic improvement.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700112
11HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
Among dulaglutide-treated patients with T2DM, glycemic responders showed greater improvement in beta-cell function than nonresponders.
In plain wordsAmong dulaglutide users with diabetes, glycemic responders had greater improvement in insulin-producing cell function than nonresponders.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableResponder beta-cell function
Study
n: not reported in source
Comparator
Nonresponders
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Responders showed greater improvement in β-cell function and more pronounced reductions in food cravings.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700106
12HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
Among dulaglutide-treated patients with T2DM, glycemic responders showed larger food-craving reductions than nonresponders.
In plain wordsAmong dulaglutide users with diabetes, glycemic responders had larger reductions in food cravings than nonresponders.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableResponder food cravings
Study
n: not reported in source
Comparator
Nonresponders
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Responders showed greater improvement in β-cell function and more pronounced reductions in food cravings.
2 context sentences(design, population, supporting numbers)
Summary · context
In this 24-week prospective observational study, 82 patients with T2DM and glycosylated hemoglobin (HbA1c) levels ≥7.0% despite standard therapy received dulaglutide 0.75 mg once weekly.
Summary · context
Glycemic responders were defined as those with an HbA1c reduction ≥0.5% and/or HbA1c <7.0% at 24 weeks.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4127700107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.